1. Home
  2. ACET vs AMTD Comparison

ACET vs AMTD Comparison

Compare ACET & AMTD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ACET
  • AMTD
  • Stock Information
  • Founded
  • ACET 1947
  • AMTD 2003
  • Country
  • ACET United States
  • AMTD France
  • Employees
  • ACET N/A
  • AMTD N/A
  • Industry
  • ACET Biotechnology: Pharmaceutical Preparations
  • AMTD
  • Sector
  • ACET Health Care
  • AMTD
  • Exchange
  • ACET Nasdaq
  • AMTD Nasdaq
  • Market Cap
  • ACET 70.3M
  • AMTD 77.3M
  • IPO Year
  • ACET N/A
  • AMTD 2019
  • Fundamental
  • Price
  • ACET $0.72
  • AMTD $1.07
  • Analyst Decision
  • ACET Buy
  • AMTD
  • Analyst Count
  • ACET 6
  • AMTD 0
  • Target Price
  • ACET $6.00
  • AMTD N/A
  • AVG Volume (30 Days)
  • ACET 324.2K
  • AMTD 17.8K
  • Earning Date
  • ACET 03-06-2025
  • AMTD 05-12-2025
  • Dividend Yield
  • ACET N/A
  • AMTD N/A
  • EPS Growth
  • ACET N/A
  • AMTD N/A
  • EPS
  • ACET N/A
  • AMTD N/A
  • Revenue
  • ACET N/A
  • AMTD $46,925,000.00
  • Revenue This Year
  • ACET N/A
  • AMTD N/A
  • Revenue Next Year
  • ACET N/A
  • AMTD N/A
  • P/E Ratio
  • ACET N/A
  • AMTD $0.88
  • Revenue Growth
  • ACET N/A
  • AMTD N/A
  • 52 Week Low
  • ACET $0.69
  • AMTD $0.96
  • 52 Week High
  • ACET $2.40
  • AMTD $1.98
  • Technical
  • Relative Strength Index (RSI)
  • ACET 37.26
  • AMTD 48.61
  • Support Level
  • ACET $0.74
  • AMTD $1.05
  • Resistance Level
  • ACET $0.91
  • AMTD $1.11
  • Average True Range (ATR)
  • ACET 0.06
  • AMTD 0.06
  • MACD
  • ACET -0.00
  • AMTD -0.00
  • Stochastic Oscillator
  • ACET 12.61
  • AMTD 20.45

About ACET Adicet Bio Inc.

Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.

About AMTD AMTD IDEA Group each representing six (6)

AMTD IDEA Group is a financial institution operating in five business segments: The capital market solutions segment assists customers in raising funds through equity and debt financing, private placements, and debt issuances. The digital solutions and other services segment provides institutional and corporate clients with paid access to enhance investor communication and relations, corporate communication also provides digital financial solution services. The Media and entertainment segment offers print and digital advertising campaigns, licensing, and marketing services including branded content, video production. The hotel operations, hospitality, and VIP services segment engages in hotel investments, hotel operations, hospitality, and VIP services; and Strategic investment segment.

Share on Social Networks: